Structure of proteins Modeling and drug design

Marcus Elstner and Tomáš Kubař

July 28, 2017

Proteins – structure and drug design

Structure of proteins


Structure of proteins

Basic principles of protein structure

- very complex, yet some structural patterns occur often
- secondary structure
 - $-\alpha$ -helix, β -strand, rare helices, several kinds of loops / turns
- role of hydrogen bonds
- tertiary structure orientation of 2° structures (β -barrel)
- quaternary structure organization of individual subunits
- native, active state of a multi-subunit protein


Structure of a polypeptide chain

- characterized by the dihedral angles along the backbone
- planar configuration on the amide bond
- two dihedral angles per AA φ (N–C $^{\alpha}$) and ψ (C $^{\alpha}$ –C)
- Ramachandran plot (1963); any amino acids lying outside of the common regions in RP would be paid special attention




Soluble / globular proteins

- surface polar and charged amino acids,
- non-polar AAs (Trp Phe Leu Ile Val) cumulate in the interior
- hydrophobic effect crucial for the stability of proteins
- folding free surface of non-polar AA side chains decreases
 - H₂O molecules are released from the 'cage' to bulk water
 - increase of entropy believed to dominate ΔG of creation of the native structure



Transmembrane proteins

- non-polar AA side chains
 - on the surface in the membrane-spanning region
 - match the hydrophobic character of the environment in the interior of the lipid membrane
- charged and polar AAs exposed to the aqueous solution



Transmembrane proteins

- resolution of structure difficult in general
- X-ray scattering approach
 - issues with crystallization of such proteins
- improved cryo-electron microscopy
 - certain advantages over X-ray scattering
 - under continuing development, as of 2015
 - involves huge amounts of computation





How cryo-EM is revolutionizing structural biology


Xiao-chen Bai, Greg McMullan, and Sjors H.W Scheres

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 00H, UK

- method to obtain a model of protein structure.
- to build 3D structure, based on comparison of the sequence to that of certain other protein(s)
- homology = structural similarity (+ evolutionary origin)
- protein structures are more conserved than protein sequences
- $lue{}$ often: similar AA sequence ightarrow nearly identical 3D structure

Trypsin	SQWVVSAA		YKSGIQVRLG	EDNINVVEGN	E.QFISASKS
Chymotrypsin	EDWVVTAA#C		GVTTSDVVVA	GEFDQGLETE	DTQVLKIGKV
Thrombin	DRWVLTAA	LLYPPWDKNF	TVDDLLVRIG	KHSRTRYERK	VEKISMLDKI
Trypsin	IVHPSYN.SN	TLNNDIMLIK	LKSAASLNSR	VASISLP	TSCASAGT
Chymotrypsin	FKNPKFS.IL	TVRNDITLLK	LATPAQFSET	VSAVCLP	SADEDFPAGM
Thrombin	YIHPRYNWKE	NLDRDIALLK	LKRPIELSDY	IHPVCLPDKQ	TAAKLLHAGF
Trypsin	QCLISGWGN.	TKSSGT	SYPDVLKCLK	APILSDSSCK	SAYPGQITSN
Chymotrypsin	LCATTGWGK.	TKYNAL	KTPDKLQQAT	LPIVSNTDCR	KYWGSRVTDV
Thrombin	KGRVTGWGNR	RETWTTSVAE	VQPSVLQVVN	LPLVERPVCK	ASTRIRITDN
Trypsin	MFCAGYLEGG	KDSCQGD	SGGPVVCS	GKLQGI	VSWGSGCAQK
Chymotrypsin	MICAGASG	VSSCMGD	SGGPLVCQ	KNGAWTLAGI	VSWGSSTCST
Thrombin	MFCAGYKPGE	GKRGDACEGD	SGGPFVMKSP	YNNRWYQMGI	VSWGEGCDRD

- method to obtain a model of protein structure.
- to build 3D structure, based on comparison of the sequence to that of certain other protein(s)
- homology = structural similarity (+ evolutionary origin)
- protein structures are more conserved than protein sequences
- $lue{}$ often: similar AA sequence ightarrow nearly identical 3D structure




- Identify a template protein that we consider homologous (there may be more than one template)
- 2 Align the sequences
 - lay them next to each other to maximize the match
- 3 Identify which regions are structurally conserved, and which are probably variable regions
- 4 Create a model (coordinates) of the conserved region 'core'
- **5** Generate the structure of the variable region(s)
 - often no regular 2° structure
- 6 Handle the AA side chains
- 7 Verify structure, and possibly refine (with MD)

Identification of the template

- template = a protein we expect to have very similar structure
- AA sequence the only input → comparison of the sequence with database of proteins with known 3D structure.
- usual choice one or more proteins with sequence similarity
- also potentially useful look for a possible function
 - provides a hint to strongly conserved fragments of sequences
 - AAs binding a cofactor or catalytic sites

Alignment of the sequences

- crucial and highly non-trivial
- choice of algorithm, scoring method, application of gap penalties
- available: FASTA (quick), Smith-Waterman, BLASTP (no gaps)
 - 1 locate regions of identity
 - 2 scan them with a scoring matrix and save the best matches
 - 3 optimally join initial regions to give a single alignment
 - 4 reoptimize alignment, centered around the best scoring region



Scoring of the alignment

- scoring method gives the quality of alignment numerically
- generally: AA identical → high contribution to the score AAs similar (conservative) but not identical → lower score very different AAs aligned → unfavorable score

several possibilities to perform the scoring:

- identity only identical AAs have favorable score.
- genetic code score = number of nucleobase changes in DNA needed to change the AA to the other/aligned one
- chemical similarity considering chemical properties of AAs example: Glu aligned with Asp scores high
- observed substitutions based on the frequency of mutations in the alignment of sequences in protein databases

Scoring functions – observed substitutions

- considered to be the best choice
- 'percentage of acceptable point mutations' (Dayhoff 1978)
 - prob. of certain mutation within evolutionary time interval
 - evol. time may be varied different range of mutations
- scoring the alignment of 3D structures rather than sequences
 - JO matrices (Johnson & Overington 1993)
 - potentially more sensitive to similarities of 3D structures,
 even if the sequences are formally less similar
- no ultimate scoring approach, most suitable universally
 - selection of the scoring matrix is non-trivial
- another decision pending global alignment (whole seq.) × local alignm. (fragment(s)) more freedom with templates

Scoring functions – observed substitutions

% probability that AA in col. *j* will have mutated to AA in row *i* by the end of the period of 250 PAM:

	ΙΑ	R	N	D	c	Q	Е	G	Н	1	1	K	М	F	Р	S	т	W	Υ	V
Ala A	13	6	9	9	5	8	9	12	6	8	6	7	7	4	11	11	11	2	4	9
Arg R	3	17	4	3	2	5	3	2	6	3	2	9	4	i	4	4	3	7	2	2
Asn N	4	4	6	7	2	5	6	4	6	3	2	5	3	2	4	5	4	2	3	3
Asp D	5	3	8	11	1	7	10	5	6	3	2	5	3	$\bar{1}$	4	5	5	1	2	3
Cys C	2	ĭ	ĭ	1	52	i	1	2	2	2	$\bar{1}$	1	ĭ	1	2	3	2	ī	4	2
Gĺn Q	3	5	5	6	1	10	7	3	8	2	3	5	3	1	4	3	3	1	2	2
Glu È	5	4	7	11	1	9	12	5	6	3	2	5	3	1	4	5	5	1	2	3
Gly G	12	5	10	10	4	7	9	27	5	5	4	6	5	3	8	11	9	2	3	7
His H	2	5	5	4	2	7	4	2	15	2	2	3	2	2	3	3	2	2	3	2
lle l	3	2	2	2	2	2	2	2	2	10	6	2	6	5	2	3	4	1	3	9
Leu L	6	4	4	3	2	6	4	3	5	15	34	4	20	13	5	4	6	6	7	13
Lys K	6	18	10	8	2	10	8	5	8	5	4	24	9	2	6	8	8	4	3	5
Met M	1	1	1	1	0	1	1	1	1	2	3	2	7	2	1	1	1	1	1	2
Phe F	2	1	2	1	1	1	1	1	3	5	6	1	4	32	1	2	2	4	20	3
Pro P	7	5	5	4	3	5	4	5	5	3	3	4	3	2	19	6	5	1	2	4
Ser S	9	6	8	7	7	6	7	9	6	5	4	7	5	3	9	10	9	4	4	6
Thr T	8	5	6	6	4	5	5	6	4	6	4	6	5	3	6	8	11	2	3	6
Trp W	0	2	0	0	0	0	0	0	1	0	1	0	0	1	0	1	0	55	1	0
Tyr Y	1	1	2	1	3	1	1	1	3	2	2	1	2	15	1	2	2	3	31	2
Val V	7	4	4	4	4	4	4	5	4	15	10	4	10	5	5	5	7	2	4	17

Gap penalty

- the alignment of sequences is allowed to be discontinuous
- this is penalized by an unfavorable contribution to the score
- simplest way: a constant negative contribution for each indel
- better: penalty = $u + v \cdot k$ for a gap of length k AAs opening penalty u > extension penalty v
- even more complex: apply larger penalty if the gap lies within a 2° structure element or even within an active center of the protein

Structurally conserved/variable regions (CR/VR)

- CRs assumed the same 3D structure in the unknown protein
- VRs will require special treatment afterwards
- more feasible if more than one template is available
- CRs usually 2° structure elements and binding sites;
 these can be recognized even with only one template
- \blacksquare more than one template? align them first with each other \to identify CRs among templates \to align the unknown protein

Create the 3D structural model

- generate the main chain in CRs simply take the template(s)
- side chains still easy for identical/similar AAs
- larger difference AAs in CRs some systematic approach to obtain a model of side chain – e.g. rotamer libraries
 – take one of the most favorable conformations
- VRs more difficult can be still copied if sequence similar
- VRs not similar look up the sequence among all proteins
- quite likely no perfect match,
 large effort in application of rotamer libraries

DB of structures from C/HM-ModBase, SwissModel Repository SwissModel via ExPASy web server, What If via EMBL servers

Evaluation and refinement of the generated structure

- \blacksquare large amount of knowledge of protein structure \to fundamental principles established, empirical rules derived
- possible criteria to check how reasonable the generated model is:
 - main chain in expected regions of the Ramachandran plot
 - planar peptide bonds
 - side chains in accordance with prev. observation / rotamer lib.
 - polar groups H-bonded to suitable partners if buried inside
 - reasonable match between hydrophilic/-phobic side chains, possibly H-bonding between polar side chains and backbone
 - no unfavorable atom—atom contacts (clashes)
 - no empty space in the interior of the structure

programs available – Procheck, 3D-Profiler the analysis may point at the suspicious regions of the structure

Evaluation and refinement of the generated structure

Final refinement of the structural model

- MM energy minimization, probably MD
- VRs free to move, restraints on CRs at the start; restraints decreased/removed during the process, gradually
- consideration of solvent implicit/explicit, maybe PBC crystallographic H₂O in CRs of template may be introduced

Proteins – structure and drug design

Molecular modeling in the drug design

 $\label{eq:modeling} \mbox{Molecular modeling in the drug design}$

One of the most exquisite applications of molecular modeling

construct new molecules to interact in a defined way
 with natural materials – proteins, nucl. acids, carbohydrates. . .

typical – 'drug design' – find a potent inhibitor of an enzyme, not interacting harmfully with other substances in the organism

difficulties:

- the drug has to be a potent inhibitor of the given enzyme
- but it must not interact with other enzymes (possibly lethal)
- it must not decompose too early
- its metabolites must not be (too) toxic

"All things are poison and nothing is without poison; only the dose makes a thing not a poison." Paracelsus (1493–1541)

hard and expensive business – several hundred million € per drug

"A pharmaceutical company utilizing computational drug design is like an organic chemist utilizing an NMR.

It won't solve all of your problems, but you are much better off with it than without it."

(David C. Young – tables / pictures from his book follow)

"Fail good, fail early."

TABLE 1.1 Typical Costs of Experiments

Experiment	Typical Cost per Compound (\$)						
Computer modeling	10						
Biochemical assay	400						
Cell culture assay	4,000						
Rat acute toxicity	12,000						
Protein crystal structure	100,000						
Animal efficacy trial	300,000						
Rat 2-year chronic oral toxicity	800,000						
Human clinical trial	500,000,000						

Moore's law: The number of transistors that can be placed inexpensively on integrated circuits doubles every $1^{1/2}$ to 2 years.

Eroom's law: The number of new drugs approved per billion US\$ spent on R&D has halved roughly every nine years since 1950.

Molecular receptors – usually proteins that are important for the processes taking place in the cell

Some estimates:

- 70 % of receptors members of 10 protein families
- 50 % of receptors 4 families: GPCR, nuclear receptors, ligand-, voltage-gated ion channels
- CATH (Class, Architecture, Topology, Homology database)
 says: there are ca. 130 druggable domains

Note: We will concentrate on structure-based drug design (SBDD)


Another approach – ligand-based drug design (LBDD)

- if active ligands are already known:
- any number of ligands
 - looking for similar molecules (2D or 3D)
- a few ligands
 - looking for a motif in the ligands pharmacophore
- many ligands (20+)
 - looking for relation between structure and activity (QSAR)

SAR paradox – even very similar molecules sometimes possess drastically different activities

Note: We will concentrate on structure-based drug design (SBDD)

Another approach – ligand-based drug design (LBDD)



- to do: find a (small) molecule (ligand, guest, key) that would bind to a protein (receptor, host, lock) as strongly and specifically as possible
 - generate the structure of a complex of a known receptor (protein) and an up to this point unknown compound
 - evaluate this structure

good news – binding site (pocket) is usually known, often – active or allosteric place of the protein

bad news:

- many degrees of freedom trans+rot+flex of the ligand
- (relaxation of protein may be often neglected)
- a single molecule can be docked manually (it helps to know the binding mode of a similar molecule) but not millions of molecules
- even such a straightforward approach may fail
 - even similar molecules may bind in different ways

sequence of tasks to accomplish:

- 1 take the compounds to test from somewhere
 - database of compounds, construct from dbase of moieties. . .
- 2 place the molecule into binding site in the most favorable way
 - pose orientation and conformation
- 3 evaluate the strength of the orientation accurate determination of ΔG impossible scoring desired


comment #1 on task 1:

Lipinski's rule of five / Pfizer's rule of five / RO5 for the 'druglikeness' of a compound:

there is no more than 1 violation of these conditions:

- no more than 5 hydrogen bond donors
- no more than 10 hydrogen bond acceptors
- molecular mass less than 500 daltons
- $lue{}$ octanol-water partition coefficient $\log P \leq 5$
- (sometimes: not more than 5 rotatable bonds)

comment #2 on task 1: frequently occuring moieties



forbidden groups: thiourea, disulfide, thiol, ester, amide, β -lactam, O-nitro, alcoxypyridinium, benzophenone, oxadiazine, fluorenone, acyl hydroquinone

Various levels of approximation may be employed

The simplest approach

- process a database of molecules
- consider each of them as rigid body
- try to fit into a rigid binding pocket in the protein
- e.g. in the Dock program ('negative image' of binding pocket as a union of several spheres)

Natural expansion

- consider the flexibility of the ligand in some way
- any means of exploring the config space of the molecule:
 - energy minimization, Monte Carlo, genetic algorithms, MD (simulated annealing)
- a simple force field

An efficient alternative

- incremental construction of the ligand
- ligand partitioned into chemically reasonable fragments
- first fragment docked in a usual way
- other fragments are 'grown' consecutively
- natural way to account for the conformational flexibility
 - relative orientation of the individual fragments

Problem of docking – it is all about sampling! No way to try to do MD for every candidate molecule

- MD takes much longer than affordable many molecules!
- MD could work probably only for quite rigid molecules and a binding pocket that does not constrain the ligand
 hardly ever the case

If our goal is to dock a single, specific molecule then a particularly thorough search with MD is possible But if we have to dock and assess many candidate ligands simpler approaches have to be chosen

State of the art

- consider flexibility of the ligands, ignore that of the protein

Quantity of interest – binding free energy But all of our free energy methods are too inefficient for docking! Needed – extremely efficient way to quantify strength of binding

- to find the right binding mode of each ligand
- to compare the strength of binding of various ligands

Solution – scoring function

- based on force fields
 - Goldscore, DOCK, Autodock
- empirical
 - parametrized against experimental binding affinities
 - several chemically motivated contributions
 - ChemScore, PLP, Glide SP/XP
- knowledge-based
 - based on Boltzmann: frequently occurring motifs must have more negative binding free energy
 - PMF, DrugScore, ASP
- based on quantum-chemical calculations
 - using semi-empirical methods

$$\Delta \textit{G}_{\mathsf{bind}} = \Delta \textit{G}_{\mathsf{solvent}} + \Delta \textit{G}_{\mathsf{conf}} + \Delta \textit{G}_{\mathsf{int}} + \Delta \textit{G}_{\mathsf{rot}} + \Delta \textit{G}_{\mathsf{t/r}} + \Delta \textit{G}_{\mathsf{vib}}$$

 $\Delta G_{
m solvent}$ – hydration changes during binding $\Delta G_{
m conf}$ – conformation of the ligand – 'deformation energy' (binding pocket may constrain the ligand, and this costs energy) $\Delta G_{
m int}$ – 'interaction energy' – specific interaction, favorable $\Delta G_{
m rot}$ – loss of entropy ($\Delta G = -T \cdot \Delta S$) by frozen rotations around single bonds, approx. $+RT\log 3 = 0.7$ kcal/mol per rotatable bond with 3 states (trans, $2 \times \text{gauche}$) $\Delta G_{
m t/r}$ – loss of trans+rot entropy upon association, approx. const.

 ΔG_{vib} – change of vib. modes (entropy), difficult, often ignored

SF is actually a kind of force field for ΔG of binding

Problem – even though it is largely approximative, it may be still computationally too costly to evaluate for a huge number of ligands that is usually to be processed.

 \rightarrow the many SF proposed so far are usually extremely simple, looking over-simplified in comparison with MM force fields.

An illustrative example (Böhm 1994):

$$\begin{split} \Delta \textit{G} &= \Delta \textit{G}_{0} &+ \Delta \textit{G}_{\mathsf{Hbond}} \cdot \sum_{\mathsf{Hbonds}} \textit{f}(\textit{R}, \alpha) + \Delta \textit{G}_{\mathsf{ionpair}} \cdot \sum_{\mathsf{ionpairs}} \textit{f}'(\textit{R}, \alpha) \\ &+ \Delta \textit{G}_{\mathsf{lipo}} \cdot \textit{A}_{\mathsf{lipo}} + \Delta \textit{G}_{\mathsf{rot}} \cdot \textit{N}_{\mathsf{rot}} \end{split}$$

 ΔG_0 – constant term $\Delta G_{\mathrm{Hbond}}$ – ideal hydrogen bond $f(R,\alpha)$ – penalty for realistic H bond (length R, angle α) $\Delta G_{\mathrm{ionpair}}$ and $f'(R,\alpha)$ – analogic quantities for ionic contacts ΔG_{lipo} – from hydrophobic interaction, proportional to the area of non-polar surface of molecule A_{lipo} N_{rot} – # of rotatable bonds in ligand being frozen upon binding

Other development:

- partition surface areas of protein and ligand polar/nonpolar, and assign different parameters to interactions polar-polar, polar-nonpolar, nonpolar-nonpolar
- statistical techniques to derive SF and its parameters

Problem of SF – only describes well tightly bound ligands Weaker binding ligands (of increasing interest in docking studies)

- rather poorly described
- binding strength possibly overestimated false positives
 Possible solution 'consensus scoring' combine several SF

Note: error of ΔG of 1.4 kcal/mol – 10× error of binding constant

- 4.2 kcal/mol of ΔG lies between micro- and nanomolar inhibitor
 - deadly difference illustrates the requirements on accuracy

Some technical details

Grid

- observation: rigid receptor is identical for many calculations
- interactions with receptor can be pre-calculated on a grid
 - each calculation of SF is then accelerated

Preparation of the receptor

- can the active site relax (change structure) upon binding?
- if yes, maybe take structure from a complex (delete ligand)
- ensemble docking use several receptor structures,
 finally choose the one to which the ligand binds most strongly
- flexible docking (partially) flexible receptor, e.g. side chains
- identify protonation states of AAs (most difficult His)


De novo design of ligands

It is very often useful to search a database of molecules, but there is still a chance to miss the 'ideal' ligand because no such compound is in the database

What about to construct the ligand 'from scratch'

- not relying on a database?
- 'outside-in' approach binding analyzed first, and tightly-binding ligand fragments proposed, then connected together (database of linkers)
 - \rightarrow molecular skeleton
- 'inside-out' approach
 - 'growing' the ligand in the binding pocket,
 driven by a search algorithm with a scoring function

De novo design of ligands



De novo design of ligands

eHiTS – example of a novel approach

